News
MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected ...
12h
Asianet Newsable on MSNIO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10xThe company said Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival compared to Keytruda ...
Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its ...
With U.S. markets hovering near record highs, many investors are turning to dividend-paying stocks as a way to balance growth ...
IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...
IO Biotech said on Monday its experimental combination cancer vaccine helped slow the disease's progression in a late-stage ...
Novo Nordisk, GSK and others need to replenish their pipelines to replace drugs coming off patent. In the past, buying a promising biotech required paying a 100% premium. But high interest rates and ...
XTRA:MRK 1 Year Share Price vs Fair Value Explore Merck KGaA's Fair Values from the Community and select yours ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results